Halozyme Therapeutics (HALO) Net Income Growth (3y) (2013 - 2026)

Halozyme Therapeutics (HALO) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - 84.25%
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 32.96%
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 30.59%
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -46.86%
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - 19.97%
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 13.80%
9 Abivax 90.15 Bn 90.15 Bn - -
10 Halozyme Therapeutics 8.24 Bn 7.92 Bn 297.47 Mn 55.88%

Historic Data

Download Data
DateValue
Mar 31, 2026 55.88%
Dec 31, 2025 -64.53%
Sep 30, 2025 41.67%
Jun 30, 2025 93.81%
Mar 31, 2025 25.25%
Dec 31, 2024 27.07%
Sep 30, 2024 -14.16%
Jun 30, 2024 0.65%
Mar 31, 2024 40.17%
Dec 31, 2023 5.28%
Sep 30, 2023 31.24%
Jun 30, 2023 42.53%
Mar 31, 2023 104.01%
Dec 31, 2022 54.35%
Sep 30, 2022 64.65%
Jun 30, 2022 52.57%
Mar 31, 2022 222.26%
Dec 31, 2021 222.06%
Sep 30, 2021 113.83%
Jun 30, 2021 81.66%